title: Conditional probability of survival nomogram for 1-, 2-, and 3-year survivors after an R0 resection for gastric cancer.
abstract: BACKGROUND
  Survival estimates after curative surgery for gastric cancer are based on AJCC staging, or on more accurate multivariable nomograms. However, the risk of dying of gastric cancer is not constant over time, with most deaths occurring in the first 2 years after resection. Therefore, the prognosis for a patient who survives this critical period improves. This improvement over time is termed conditional probability of survival (CPS). Objectives of this study were to develop a CPS nomogram predicting 5-year disease-specific survival (DSS) from the day of surgery for patients surviving a specified period of time after a curative gastrectomy and to explore whether variables available with follow-up improve the nomogram in the follow-up setting.
  
  
  METHODS
  A CPS nomogram was developed from a combined US-Dutch dataset, containing 1,642 patients who underwent an R0 resection with or without chemotherapy/radiotherapy for gastric cancer. Weight loss, performance status, hemoglobin, and albumin 1 year after resection were added to the baseline variables of this nomogram.
  
  
  RESULTS
  The CPS nomogram was highly discriminating (concordance index: 0.772). Surviving 1, 2, or 3 years gives a median improvement of 5-year DSS from surgery of 7.2, 19.1, and 31.6 %, compared with the baseline prediction directly after surgery. Introduction of variables available at 1-year follow-up did not improve the nomogram.
  
  
  CONCLUSIONS
  A robust gastric cancer nomogram was developed to predict survival for patients alive at time points after surgery. Introduction of additional variables available after 1 year of follow-up did not further improve this nomogram.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: Johan L
authors.initials: JL
authors.lastname: Dikken
authors.forename: Raymond E
authors.initials: RE
authors.lastname: Baser
authors.forename: Mithat
authors.initials: M
authors.lastname: Gonen
authors.forename: Michael W
authors.initials: MW
authors.lastname: Kattan
authors.forename: Manish A
authors.initials: MA
authors.lastname: Shah
authors.forename: Marcel
authors.initials: M
authors.lastname: Verheij
authors.forename: Cornelis J H
authors.initials: CJ
authors.lastname: van de Velde
authors.forename: Murray F
authors.initials: MF
authors.lastname: Brennan
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Coit
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000368:Aged; D017024:Chemotherapy, Adjuvant; D005260:Female; D005544:Forecasting / Q000379:methods; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D049451:Nomograms; D011336:Probability; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D013274:Stomach Neoplasms / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome